Alkermes (NASDAQ:ALKS) Releases Earnings Results, Beats Estimates By $0.11 EPS

Alkermes (NASDAQ:ALKS) announced its earnings results on Wednesday. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11, Zacks reports. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Stock Performance

NASDAQ ALKS opened at $33.50 on Thursday. The firm has a market cap of $5.42 billion, a P/E ratio of 17.18, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is $30.16 and its 200-day moving average is $28.65. Alkermes has a 12-month low of $22.90 and a 12-month high of $33.73.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Alkermes in a research report on Tuesday. They set a “buy” rating and a $40.00 target price on the stock. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and lifted their price target for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. Cantor Fitzgerald reduced their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 target price (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Finally, The Goldman Sachs Group cut their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.08.

Insider Buying and Selling

In other Alkermes news, SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the transaction, the senior vice president now owns 60,703 shares of the company’s stock, valued at $1,769,492.45. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Craig C. Hopkinson sold 9,221 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $31.50, for a total transaction of $290,461.50. Following the completion of the sale, the executive vice president now directly owns 59,730 shares in the company, valued at approximately $1,881,495. The trade was a 13.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 179,189 shares of company stock valued at $5,723,518. Company insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.